AR3 CAUSES AND EFFECTS OF SCENARIO REJECTION STATED PREFERENCES FOR RHEUMATOID ARTHRITIS TREATMENTS.pdf.pdf

Volume 10 • Number 3 • 2007
VALUE IN HEALTH
ISPOR Twelfth Annual International Meeting
Contributed Presentation Abstracts
Contributed Podium Presentations
PODIUM SESSION I: ARTHRITIS OBJECTIVES: To evaluate the impact of co-existing IMIDs on
health care costs in RA patients. METHODS: A retrospective
AR1 study utilizing administrative claims data from Blue Cross Blue
COST-EFFECTIVENESS OF ETANERCEPT AND INFLIXIMAB IN Shield health plans was conducted. Patients initiating anti-TNF
THE REAL-WORLD SETTING—AN ESTIMATE BASED ON (infliximab, etanercept, or adalimumab) therapy between January
PUBLISHED GERMAN DATA ON RESPONSE AND ADHERENCE 1, 2003 and June 30, 2005, were required to have >6 months of
Ekelund M1, Deeg M2, Runge C2 continuous eligibility prior to and >12 months following their
1Wyeth AB, Solna, Sweden, 2Wyeth Pharma GmbH, Münster, index date. Two mutually exclusive groups were developed based
Germany on the number of IMIDs (RA, psoriatic arthritis, ankylosing
OBJECTIVES: Anti-TNF-α drugs (Biologics) have e a cor- spondylitis, psoriasis, Crohn’s disease, or ulcerative colitis) diag-
nerstone in the treatment of Rheumatoid Arthritis (RA). Since noses: RA and RA plus >1 other IMID (RA + IMID). The Charl-
initial choice of agents is sometimes driven by expected treatment son-orbidity Index (CDCI) was used to control for
costs and related cost-effectiveness